EMA Authorised: Opfolda (miglustat) — Amicus Therapeutics Europe Limited

View source ↗

Summary

The EMA authorised Opfolda (miglustat) for the treatment of Pompe disease (Glycogen Storage Disease Type II), with Amicus Therapeutics Europe Limited as the mar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pompe Disease

Drugs mentioned

• OPFOLDA (Miglustat)

Snippet

Status: Authorised. Therapeutic area: Glycogen Storage Disease Type II. MAH: Amicus Therapeutics Europe Limited. Decision date: 24/10/2024